Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease

Edoardo Monfrini, Alessio Di Fonzo

Research output: Chapter in Book/Report/Conference proceedingChapter

11 Citations (Scopus)

Abstract

The discovery of LRRK2 mutations as a cause of Parkinson’s disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research. Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide. The G2385R and R1628P variants represent validated risk factors for PD in Asian populations. Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations. Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2. Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling. In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.

Original languageEnglish
Title of host publicationAdvances in Neurobiology
PublisherSpringer New York LLC
Pages3-30
Number of pages28
Volume14
DOIs
Publication statusPublished - Apr 1 2017

Publication series

NameAdvances in Neurobiology
Volume14
ISSN (Print)2190-5215

Fingerprint

Inborn Genetic Diseases
Leucine
Parkinson Disease
Phosphotransferases
Mutation
Epidemiology
Penetrance
Genetic Counseling
Genetic Testing
Research
Haplotypes
Population
Genetics
Guidelines
Testing

Keywords

  • Dardarin
  • Familial Parkinson’s disease
  • Leucine-rich repeat kinase 2
  • LRRK2
  • LRRK2 mutations
  • PARK8
  • Parkinson’s disease
  • Parkinson’s disease genetics

ASJC Scopus subject areas

  • Biochemistry
  • Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience

Cite this

Monfrini, E., & Di Fonzo, A. (2017). Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease. In Advances in Neurobiology (Vol. 14, pp. 3-30). (Advances in Neurobiology; Vol. 14). Springer New York LLC. https://doi.org/10.1007/978-3-319-49969-7_1

Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease. / Monfrini, Edoardo; Di Fonzo, Alessio.

Advances in Neurobiology. Vol. 14 Springer New York LLC, 2017. p. 3-30 (Advances in Neurobiology; Vol. 14).

Research output: Chapter in Book/Report/Conference proceedingChapter

Monfrini, E & Di Fonzo, A 2017, Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease. in Advances in Neurobiology. vol. 14, Advances in Neurobiology, vol. 14, Springer New York LLC, pp. 3-30. https://doi.org/10.1007/978-3-319-49969-7_1
Monfrini E, Di Fonzo A. Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease. In Advances in Neurobiology. Vol. 14. Springer New York LLC. 2017. p. 3-30. (Advances in Neurobiology). https://doi.org/10.1007/978-3-319-49969-7_1
Monfrini, Edoardo ; Di Fonzo, Alessio. / Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease. Advances in Neurobiology. Vol. 14 Springer New York LLC, 2017. pp. 3-30 (Advances in Neurobiology).
@inbook{1244163727334ebd9be663213c298b11,
title = "Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease",
abstract = "The discovery of LRRK2 mutations as a cause of Parkinson’s disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research. Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide. The G2385R and R1628P variants represent validated risk factors for PD in Asian populations. Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations. Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2. Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling. In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.",
keywords = "Dardarin, Familial Parkinson’s disease, Leucine-rich repeat kinase 2, LRRK2, LRRK2 mutations, PARK8, Parkinson’s disease, Parkinson’s disease genetics",
author = "Edoardo Monfrini and {Di Fonzo}, Alessio",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/978-3-319-49969-7_1",
language = "English",
volume = "14",
series = "Advances in Neurobiology",
publisher = "Springer New York LLC",
pages = "3--30",
booktitle = "Advances in Neurobiology",

}

TY - CHAP

T1 - Leucine-rich repeat kinase (LRRK2) genetics and parkinson’s disease

AU - Monfrini, Edoardo

AU - Di Fonzo, Alessio

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The discovery of LRRK2 mutations as a cause of Parkinson’s disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research. Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide. The G2385R and R1628P variants represent validated risk factors for PD in Asian populations. Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations. Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2. Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling. In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.

AB - The discovery of LRRK2 mutations as a cause of Parkinson’s disease (PD), including the sporadic late-onset form, established the decisive role of genetics in the field of PD research. Among LRRK2 mutations, the G2019S, mostly lying in a haplotype originating from a common Middle Eastern ancestor, has been identified in different populations worldwide. The G2385R and R1628P variants represent validated risk factors for PD in Asian populations. Here, we describe in detail the origin, the present worldwide epidemiology, and the penetrance of LRRK2 mutations. Furthermore, this chapter aims to characterize other definitely/probably pathogenic mutations and risk variants of LRRK2. Finally, we provide some general guidelines for a LRRK2 genetic testing and counseling. In summary, LRRK2 discovery revolutionized the understanding of PD etiology and laid the foundation for a promising future of genetics in PD research.

KW - Dardarin

KW - Familial Parkinson’s disease

KW - Leucine-rich repeat kinase 2

KW - LRRK2

KW - LRRK2 mutations

KW - PARK8

KW - Parkinson’s disease

KW - Parkinson’s disease genetics

UR - http://www.scopus.com/inward/record.url?scp=85017174194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017174194&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-49969-7_1

DO - 10.1007/978-3-319-49969-7_1

M3 - Chapter

VL - 14

T3 - Advances in Neurobiology

SP - 3

EP - 30

BT - Advances in Neurobiology

PB - Springer New York LLC

ER -